← Back to Search

Other

UCT-03-008 for Advanced Solid Cancers

Phase 1
Recruiting
Research Sponsored by 1200 Pharma, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Advanced solid tumor
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will study a new drug to see if it is safe and effective in treating patients with advanced solid tumors.

Who is the study for?
This trial is for adults with advanced solid tumors that can be measured, who are in fairly good health (able to perform daily activities without significant assistance), and have their major organs working well. Pregnant or breastfeeding women, those not recovered from previous cancer treatments, or anyone who has had certain treatments within the last 14-28 days cannot join.Check my eligibility
What is being tested?
The study is testing UCT-03-008's safety and how well it works against advanced solid tumors. It will also look at how the body processes the drug. This is the first time humans are being given this treatment to see if it could be a new option for tumor therapy.See study design
What are the potential side effects?
Since this is a first-in-human study of UCT-03-008, specific side effects aren't yet known but may include typical reactions such as nausea, fatigue, allergic responses or more serious complications depending on how the drug affects different people.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My cancer is in an advanced stage and not just in one place.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of adverse events and serious adverse events
Maximum Tolerated Dose (MTD)
Recommended Phase 2 Dose (RP2D)
Secondary outcome measures
1 Year Overall Survival (1YOS)
2 Year Overall Survival (2YOS)
Apparent Clearance (CL/F) of UCT-03-008
+14 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Expansion as Monotherapy - Part 2Experimental Treatment1 Intervention
UCT-03-008 RP2D Expansion
Group II: Dose Finding as Monotherapy - Part 1Experimental Treatment1 Intervention
UCT-03-008 Dose Finding

Find a Location

Who is running the clinical trial?

1200 Pharma, LLCLead Sponsor
1 Previous Clinical Trials
32 Total Patients Enrolled
Translational Research in OncologyOTHER
21 Previous Clinical Trials
6,609 Total Patients Enrolled
Alex GarciaStudy DirectorTRIO-US

Media Library

UCT-03-008 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05103046 — Phase 1
Solid Tumors Research Study Groups: Dose Finding as Monotherapy - Part 1, Expansion as Monotherapy - Part 2
Solid Tumors Clinical Trial 2023: UCT-03-008 Highlights & Side Effects. Trial Name: NCT05103046 — Phase 1
UCT-03-008 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05103046 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what degree does UCT-03-008 endanger humans?

"Because of the limited data on safety and efficacy, UCT-03-008 was rated a 1 by our team at Power."

Answered by AI

What aims are being pursued with this research endeavor?

"Over the course of two years, this trial seeks to identify a Recommended Phase 2 Dose (RP2D). Additional objectives include ascertaining Minimum Plasma UCT-03-008 Concentration at steady state (Cmin,ss), determining Time to Response (TTR) from start of treatment until either complete or partial response is achieved, and assessing Maximum Plasma UCT-03-008 Concentration at steady state (Cmax,ss)."

Answered by AI

What is the maximum capacity of this research study?

"Affirmative. According to the clinicaltrials.gov webpage, this project is actively seeking participants and needs 68 people from 3 different sites. The trial was first made public on December 23rd 2021 and its information has been updated as recently as July 25th 2022."

Answered by AI

Is enrollment currently available for this trial?

"Affirmative. According to clinicaltrials.gov, this medical study is actively looking for participants and was first published on December 23rd 2021 with the latest update occurring July 25th 2022. The research team seeks 68 individuals across 3 locations."

Answered by AI
~16 spots leftby Dec 2024